BiotechTube

Bilastine Ophthalmic Solution 0.6% + Ketotifen Ophthalmic Solution 0.025% (Zaditen) + Vehicle of Bilastine Ophthalmic Solution

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Allergic Conjunctivitis

Conditions

Allergic Conjunctivitis

Trial Timeline

Apr 7, 2018 → Aug 10, 2018

NCT ID
NCT03479307

About Bilastine Ophthalmic Solution 0.6% + Ketotifen Ophthalmic Solution 0.025% (Zaditen) + Vehicle of Bilastine Ophthalmic Solution

Bilastine Ophthalmic Solution 0.6% + Ketotifen Ophthalmic Solution 0.025% (Zaditen) + Vehicle of Bilastine Ophthalmic Solution is a phase 3 stage product being developed by Faes Farma for Allergic Conjunctivitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03479307. Target conditions include Allergic Conjunctivitis.

What happened to similar drugs?

20 of 20 similar drugs in Allergic Conjunctivitis were approved

Approved (20) Terminated (3) Active (0)
✅placebo, isotonic ciclesonide, hypotonic ciclesonideSumitomo PharmaApproved
✅ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
✅Cetirizine + LoratadineJohnson & JohnsonApproved
✅Budesonide + PlaceboAstraZenecaApproved
✅Ciclesonide nasal spray + placebo Azelastine + Ciclesonide nasal spray + AzelastineAstraZenecaApproved
✅epinastine HCL and olopatadine HCLMerckApproved
✅Placebo + Montelukast + Fluticasone propionateMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03479307Phase 3Completed

Competing Products

20 competing products in Allergic Conjunctivitis

See all competitors
ProductCompanyStageHype Score
BriquilimabJasper TherapeuticsPhase 1
11
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
47
Lesigercept + PlaceboYuhanPhase 2
42
YH35324 + Omalizumab + PlaceboYuhanPhase 1
29
Bilastine + Desloratadine + PlaceboYuhanPhase 3
40
ASP2390 + PlaceboAstellas PharmaPhase 1
33
ASP4070 + PlaceboAstellas PharmaPhase 2
35
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
35
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
35
Prednisolone + VoriconazoleCiplaPhase 2/3
38
placebo, isotonic ciclesonide, hypotonic ciclesonideSumitomo PharmaApproved
35
ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
43
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalationSumitomo PharmaPhase 3
40
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
40
ciclesonide nasal aerosol + mometasone Aqueous (AQ) nasal spraySumitomo PharmaPhase 1
29
ciclesonide + mometasoneSumitomo PharmaPhase 3
40
DSP-3025 + PlaceboSumitomo PharmaPhase 1
29
ciclesonide nasal aerosol + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA 80 mcg + Ciclesonide HFA 160 mcg + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mgSumitomo PharmaPhase 3
40